Omega Fund Management LLC lessened its stake in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 51.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 526,357 shares of the company's stock after selling 550,000 shares during the quarter. enGene comprises about 2.9% of Omega Fund Management LLC's holdings, making the stock its 7th biggest holding. Omega Fund Management LLC owned 1.19% of enGene worth $3,500,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Deep Track Capital LP grew its holdings in enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock valued at $30,308,000 after purchasing an additional 1,949,942 shares during the last quarter. Fcpm Iii Services B.V. grew its holdings in enGene by 11.0% during the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock valued at $64,057,000 after purchasing an additional 954,610 shares in the last quarter. Franklin Resources Inc. increased its position in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Blue Owl Capital Holdings LP boosted its holdings in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after buying an additional 101,006 shares during the period. Finally, Corton Capital Inc. acquired a new stake in enGene in the 4th quarter valued at approximately $157,000. 64.16% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on ENGN shares. JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of enGene in a report on Tuesday, April 29th. Piper Sandler started coverage on shares of enGene in a report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 target price on the stock. UBS Group downgraded enGene from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of enGene in a research note on Tuesday, March 11th. Finally, Morgan Stanley decreased their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, enGene presently has a consensus rating of "Buy" and an average price target of $23.29.
View Our Latest Research Report on enGene
enGene Price Performance
Shares of ENGN stock opened at $2.97 on Tuesday. The business's fifty day moving average is $4.34 and its 200 day moving average is $6.22. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $151.40 million, a price-to-earnings ratio of -5.12 and a beta of -0.36. enGene Holdings Inc. has a twelve month low of $2.70 and a twelve month high of $14.37.
enGene Profile
(
Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
